Biolase, Inc.
BIOL
BIOL was delisted on the 18th of June, 2024.
21 hedge funds and large institutions have $2.07M invested in Biolase, Inc. in 2020 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 4 increasing their positions, 2 reducing their positions, and 5 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 2
20% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 5
0% more funds holding
Funds holding: 21 → 21 (0)
54% less capital invested
Capital invested by funds: $4.51M → $2.07M (-$2.44M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$220K |
| 2 |
Jane Street
New York
|
+$49K |
| 3 |
ICM
Invenomic Capital Management
Boston,
Massachusetts
|
+$25.1K |
| 4 |
ECM
ETrade Capital Management
Arlington,
Virginia
|
+$15.9K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$15.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OIM
Oracle Investment Management
Greenwich,
Connecticut
|
-$1.56M |
| 2 |
ACM
Archon Capital Management
Seattle,
Washington
|
-$1M |
| 3 |
WPC
White Pine Capital
Bloomington,
Minnesota
|
-$241K |
| 4 |
WVP
Worth Venture Partners
Fort Lee,
New Jersey
|
-$212K |
| 5 |
BlackRock
New York
|
-$17.1K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Morgan Stanley
New York
| – | -$2.28K | -2 | Closed |
|
BIOL Hedge Fund Activity: Q2 2020 in Review
21 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Biolase, Inc. (BIOL) for Q2 2020, worth a combined $2.07M — down 54% from $4.51M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new BIOL positions and 5 closed out — a net gain of 1 holder — while 4 added to existing stakes and 2 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $220K. The largest seller was Oracle Investment Management, cutting an estimated $1.56M.
- 21 institutional investors held Biolase, Inc. (BIOL) as of Q2 2020, unchanged from Q1 2020.
- Funds reported $2.07M of Biolase, Inc. stock for Q2 2020, down 54% quarter-over-quarter.
- 6 funds opened new Biolase, Inc. positions in Q2 2020 and 5 closed out, a net change of +1 holder.
- The largest Biolase, Inc. buyer in Q2 2020 was Renaissance Technologies, an estimated $220K added.
- The largest Biolase, Inc. seller in Q2 2020 was Oracle Investment Management, an estimated $1.56M sold.
Based on aggregated 13F filings for Q2 2020.